Skip to content

    Research Use Only

    This site is an independent educational resource for research compounds. We do not sell, distribute, or endorse human consumption of any compound. By entering, you confirm you are 21 years of age or older and agree to our Terms & Privacy Policy.

    🔬 100K+ researchers trust BodyHackGuide — Join r/BodyHackGuide
    Growth Hormone / IGF-1 AxisPhase II

    GHRP-6 Dosage Guide: Protocols, Calculator & Safety

    Everything you need to know about GHRP-6 dosing — protocols, safety, and where to buy.

    Dose Range

    100–300 mcg per injection

    Frequency

    1–3 times daily

    Cycle Length

    8–12 weeks

    Half-Life

    ~20–30 minutes

    Administration Routes

    SubcutaneousIntramuscular

    Quick Reconstitution Calculator

    Calculate syringe units instantly

    Syringe Draw

    10.0 units

    2500 mcg/ml · 0.100 ml draw

    Full Tool

    Dosing Protocols

    Beginner

    Standard beginner protocol:

    • Dose: 100 mcg subcutaneous per injection
    • Frequency: 2-3x daily
    • Timing: Fasted — pre-breakfast, pre-training, and/or pre-bed
    • Duration: 12-16 weeks minimum to assess response

    Reconstitution: Typical 5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL. A 100 mcg dose = 0.04 mL = 4 units on a U-100 insulin syringe.

    Meal planning is critical:

    Unlike GHRP-2 or ipamorelin, GHRP-6's pronounced appetite effect requires proactive meal planning:

    • Have a planned, satisfying meal ready to eat within 30-60 minutes of each injection
    • Inject at times that align with planned meal windows (pre-breakfast if you eat breakfast; pre-dinner if it's your larger meal)
    • Avoid injecting 90+ minutes before a planned meal — the hunger will drive you to snack and sabotage macro planning

    Timing options:

    Option A — Three daily doses (most effective for GH goals):

    • 07:00 (pre-breakfast, fasted overnight)
    • 13:00 (pre-training if training mid-day; otherwise pre-lunch in deficit scenarios this is less effective)
    • 22:00 (pre-bed, 2+ hours after dinner)

    Option B — Two daily doses (simpler):

    • 07:00 (pre-breakfast)
    • 22:00 (pre-bed)

    The 2-dose protocol misses the pre-training GH amplification but is more sustainable and produces less cumulative cortisol/prolactin exposure.

    Labs to run before starting: IGF-1, fasting insulin, fasting glucose, HbA1c, comprehensive metabolic panel, prolactin (if sensitive), AM cortisol (if HPA concerns). Recheck at week 8 and week 16.

    First-week observations:

    • Appetite increase should be clearly noticeable within the first 2-3 doses
    • Flushing and injection site redness usually diminish after the first week
    • Vivid dreams begin within 3-5 days of bedtime dosing
    • Measurable body composition effects take 8-12 weeks
    Standard

    Optimized intermediate protocol:

    • Dose: 150-200 mcg SC per injection
    • Frequency: 2-3x daily (fasted)
    • Stack: Paired with a GHRH analog for synergistic effect

    GHRP-6 + GHRH stack (standard):

    • GHRP-6: 150-200 mcg SC
    • Sermorelin: 200-300 mcg SC, OR
    • CJC-1295 (no-DAC): 100-200 mcg SC, OR
    • Tesamorelin: 1 mg SC (if VAT reduction is also a goal)
    • Draw both into same insulin syringe and inject together

    Synergistic rationale: GHRP-6 provides the ghrelin-pathway signal; GHRH analog provides the parallel GHRH-pathway signal. Intracellular convergence produces GH pulse amplitude 3-5x either alone (Bowers 1991).

    Caloric surplus synergy:

    The appetite-stimulating effect of GHRP-6 makes it uniquely well-suited to bulking phases, where:

    • Higher caloric intake is desired but natural hunger is limiting
    • GH/IGF-1 amplification enhances lean mass gains from the surplus
    • The "eat more, build more" feedback loop is productive

    Some practitioners specifically use GHRP-6 during 12-16 week lean bulk phases and then switch to ipamorelin for cut/maintenance phases to avoid the hunger during deficit periods.

    Cycling strategy:

    • 5 days on / 2 days off weekly — weekend pauses maintain GHS-R1a sensitivity
    • 8 weeks on / 2 weeks off — macro cycling for full receptor reset
    • 12-16 week phases alternating with ipamorelin or GHRP-2 based on current training and caloric phase

    Progressive dosing:

    • Weeks 1-2: 100 mcg 2x daily (establish appetite tolerance and meal planning)
    • Weeks 3-4: 100 mcg 3x daily
    • Weeks 5-8: 150 mcg 3x daily
    • Weeks 9+: 200 mcg 3x daily (if IGF-1 response warrants)

    Doses beyond 200 mcg per injection show diminishing returns due to receptor saturation.

    Advanced

    Advanced protocol considerations:

    Most advanced users either switch to alternative GHS compounds after the initial GHRP-6 phase or integrate it strategically into phase-based programming.

    Situations where GHRP-6 is the best choice:

    • Bulking / caloric surplus phase — appetite stimulation is a feature
    • Recovery from illness where appetite restoration is the primary goal
    • Geriatric populations with anorexia of aging — appetite and GH-axis stimulation both address age-related decline
    • Cachexia protocols — research context, under medical supervision

    Situations where GHRP-6 is not the right choice:

    • Cutting / caloric deficit — use ipamorelin or GHRP-2 instead
    • GLP-1 agonist users (semaglutide, tirzepatide, retatrutide) — appetite signals actively oppose each other; defeats the GLP-1 purpose
    • Users with baseline anxiety or HPA axis concerns — cortisol elevation, while modest, is unhelpful
    • Chronic daily long-term use beyond 4-6 months — transition to ipamorelin for cleaner chronic pharmacology

    Full bulk-phase performance stack (12-16 weeks):

    • GHRP-6: 200 mcg SC × 3 daily (pre-breakfast, pre-training, pre-bed)
    • CJC-1295 no-DAC: 100 mcg SC × 3 daily (same injection as GHRP-6)
    • BPC-157: 500 mcg SC × 2 daily (connective tissue support under anabolic training)
    • TB-500: 2-2.5 mg SC × 2 weekly (soft tissue remodeling)
    • Testosterone replacement if documented hypogonadism

    This stack requires rigorous macro planning — the appetite stimulus will drive overshooting calories and fat gain unless meals are prepared and tracked.

    Combinations to avoid:

    • GHRP-6 + GHRP-2: Redundant mechanism class
    • GHRP-6 + hexarelin: Redundant; hexarelin has even stronger cortisol/prolactin effects
    • GHRP-6 + MK-677: Redundant GHS-R1a mechanism; MK-677 alone provides 24-hour coverage
    • GHRP-6 + ipamorelin: Same receptor; choose one
    • GHRP-6 + exogenous HGH: Pointless; exogenous GH suppresses endogenous pituitary output
    • GHRP-6 + GLP-1 agonists during deficit: Directly opposing appetite signals; choose the goal

    Discontinuation triggers: Persistent joint pain, peripheral edema, carpal tunnel symptoms, fasting glucose persistently above 110 mg/dL, unexpected body composition change, worsening sleep apnea, or significant cortisol/prolactin elevation on labs.

    Weight-Based Dosing

    1–2 mcg/kg per injection.

    Commonly Stacked With

    Synergistic Combinations

    GHRP-6 + GHRH analog (sermorelin, CJC-1295 no-DAC, or tesamorelin): Classical GHS+GHRH synergy. GH pulse amplitude amplified 3-5x vs either alone (Bowers 1991). Inject simultaneously SC, 2-3x daily fasted.

    GHRP-6 + BPC-157 + TB-500: Standard peptide-enhanced recovery stack for bulking phases. GHRP-6 drives systemic anabolism and caloric intake; BPC-157 supports connective tissue adaptation to increased training load; TB-500 accelerates soft tissue remodeling.

    GHRP-6 + Testosterone optimization (in hypogonadal men): Additive anabolic effects, particularly during bulking phases where both the hormonal substrate and the GH axis are optimized.

    Situational / Context-Specific

    GHRP-6 + NAD+ / mitochondrial support: Non-interfering. Different pathway. Works in longevity-focused protocols where GH-axis and mitochondrial health are both targeted.

    GHRP-6 + Epithalon: Non-interfering; complementary for anti-aging protocols. Epithalon supports pineal function and telomere maintenance; GHRP-6 supports GH/IGF-1 axis. Different mechanisms.

    Avoid or Reconsider

    GHRP-6 + GHRP-2 or Hexarelin: Redundant mechanism (all GHS-R1a agonists). No synergy; no benefit over single-compound dosing.

    GHRP-6 + Ipamorelin: Same receptor. Pick based on appetite goal — GHRP-6 for hunger stimulation, ipamorelin for clean GH without appetite effect.

    GHRP-6 + MK-677: Both GHS-R1a agonists. MK-677 provides 24-hour receptor occupancy; adding short-pulse GHRP-6 produces diminishing returns. Choose one.

    GHRP-6 + GLP-1 agonists (semaglutide, tirzepatide, retatrutide): Directly opposing appetite signals. GHRP-6 stimulates hunger; GLP-1s suppress it. Stacking defeats the purpose of both. If you need lean mass protection during a GLP-1 cut, use ipamorelin or GHRP-2 at minimum dose instead.

    Pharmacologically Counterproductive

    GHRP-6 + exogenous recombinant HGH: Exogenous GH suppresses endogenous GHRH and somatotroph activity via IGF-1 negative feedback. GHRP-6 becomes functionally inert.

    GHRP-6 + aggressive glucocorticoid therapy: Reduced GH response under pharmacologic steroid context; both agents can additively disrupt glucose homeostasis.

    Related Compound Pages

    • GHRP-2 — Close analog with stronger GH potency, less appetite stimulation
    • Ipamorelin — Cleaner GHS-R1a agonist; minimal appetite and cortisol effects
    • Hexarelin — Most potent GHS but with highest cortisol/prolactin cross-effects
    • Sermorelin — Pulsatile GHRH synergy partner
    • CJC-1295 — GHRH analog synergy partner
    • Tesamorelin — FDA-approved GHRH analog
    • MK-677 — Oral long-acting GHS alternative
    • BPC-157 — Tissue repair stack partner
    • TB-500 — Soft tissue remodeling stack partner
    • NAD+ — Mitochondrial longevity stack partner

    Side Effects & Safety

    ## Very Common (expected in most users) - **Strong appetite stimulation / hunger** — The signature effect of GHRP-6, noticeable within 30-60 minutes of injection. For users in caloric surplus, this is often welcome. For users in deficit, this is frequently the primary reason to switch to GHRP-2 or ipamorelin. - **Injection site reactions** — Mild erythema, transient itching at SC injection site. Rotating sites minimizes. - **Flushing** — Pink/red flush of face and neck post-injection, fading in 15-30 minutes. - **Vivid dreams** — Commonly reported with bedtime dosing; associated with enhanced slow-wave sleep. ## Common - **Transient cortisol elevation** — +15-25% above baseline for 60-90 minutes post-injection. Similar to GHRP-2. Usually clinically trivial in healthy users but relevant in users with HPA axis concerns, anxiety disorders, or adrenal insufficiency. - **Mild prolactin elevation** — Usually clinically trivial but relevant in users with baseline prolactin-sensitive conditions. - **Mild fluid retention** — Particularly first 2-3 weeks of daily use. Self-limiting. - **Transient insulin sensitivity reduction** — GH-axis stimulation modestly reduces insulin sensitivity over time. Monitor HbA1c and fasting insulin in extended use. - **Mild headache** — Uncommon; typically responsive to hydration. ## Less Common - **Nausea** — More common with high doses (>300 mcg) or IV administration. Rare at standard SC doses. - **Transient hypotension** — Primarily with IV administration; SC route rarely produces meaningful blood pressure effects. - **Paresthesia / scalp tingling** — Transient, benign. - **Dysgeusia** — Unusual taste immediately post-injection. ## Dose-Dependent with Long-term Use - **Weight gain** — Not the GH-mediated lean mass gain but actual weight gain from sustained appetite stimulation if caloric intake is not managed. Users consistently report the need for disciplined meal planning to prevent overshooting intended calories. - **Insulin resistance** — Modest but measurable with chronic daily high-dose use over months. HbA1c monitoring at 3-month intervals is reasonable. - **GHS-R1a receptor desensitization** — Chronic high-frequency dosing produces measurable tachyphylaxis. Cycling (5 on / 2 off weekly, or 8 on / 2 off macro) helps maintain responsiveness. - **Cumulative HPA axis effects** — Repeated low-grade cortisol elevation over months could theoretically contribute to dysregulation in susceptible users. ## Theoretical Long-term Concerns Like all GH-axis interventions, sustained IGF-1 elevation raises theoretical concerns around chronic mitogenic signaling and cancer risk. No causal link has been demonstrated, but mechanistic plausibility supports conservative dosing, periodic IGF-1 monitoring, and avoidance in users with active malignancy or strong family history of hormonally-responsive cancers. ## Signs You Are Overdosing - Persistent joint discomfort or peripheral edema - Carpal tunnel symptoms - Persistent fasting glucose elevation (>110 mg/dL) - Unexpected weight gain beyond what your caloric intake accounts for - Sleep apnea worsening Any of these warrant dose reduction or discontinuation.

    Contraindications

    GHRP-6 is contraindicated or requires extreme caution in: - **Active malignancy** — particularly hormone-responsive cancers; IGF-1 elevation theoretical tumor-promotion risk - **Strong family history of GH-axis sensitive cancers** — specialist supervision required - **Pregnancy and lactation** — no established safety data - **Known hypersensitivity** to GHRP-6, related hexapeptides, or any excipient - **Severe untreated obstructive sleep apnea** — theoretical concern about airway soft-tissue growth; stabilize with CPAP/APAP first - **Acute critical illness** — GH-axis stimulation inappropriate during sepsis, post-surgical recovery, multiple trauma, or respiratory failure - **Diabetic ketoacidosis or severe uncontrolled diabetes** — resolve metabolic state first - **Active proliferative retinopathy** — relative contraindication - **Hypothalamic-pituitary disease with untreated adrenal insufficiency** — the residual cortisol effect may be unreliable; specialist supervision required - **Prolactinoma or clinically significant hyperprolactinemia** — the modest prolactin elevation could complicate management - **Binge eating disorder, bulimia, or other active eating disorders** — the appetite-stimulating effect is contraindicated given the underlying pathology **Relative cautions (monitor closely):** - Borderline fasting glucose or elevated HbA1c — GH-axis effects tip toward insulin resistance - Cushing's syndrome or baseline elevated cortisol — GHRP-6 adds to HPA load - Anxiety disorders or HPA axis dysregulation — cortisol elevation may be poorly tolerated - Uncontrolled GERD / reflux disease — ghrelin-receptor agonism stimulates gastric motility and acid secretion; symptoms may worsen - Active weight-loss phase — directly opposed to GHRP-6's appetite effect; consider alternatives - Concurrent GLP-1 agonist therapy — actively opposing appetite signals; defeats the goals of both - Strong family history of colon polyps — baseline colonoscopy before starting - Concurrent glucocorticoid therapy — pharmacodynamic interference **Drug interactions:** - **Glucocorticoids:** Reduced GH response; pharmacodynamic interference - **GLP-1 receptor agonists:** Directly opposing appetite pharmacology; defeats the purpose of both - **Opioids:** Can augment the cortisol and prolactin effects of GHRP-6 - **Thyroid hormone replacement:** GH-axis changes can alter thyroid requirements; monitor TSH periodically - **Exogenous GH:** Pharmacologically counterproductive; the combination is pointless **Discontinuation triggers:** - Persistent joint pain, carpal tunnel symptoms, or peripheral edema - Persistent fasting glucose >110 mg/dL - Cushingoid body composition changes (buffalo hump, moon face, central obesity beyond baseline) - Worsening sleep apnea - Unexpected weight gain beyond managed caloric intake - Development of eating disorder patterns or loss of control around food - Any cardiovascular symptoms

    Check interactions with the Interaction Checker →

    Additional Notes

    Standard Dosing Reference

    User Tier Per Injection Frequency Daily Total
    Beginner 100 mcg 2x/day 200 mcg
    Intermediate 100-150 mcg 3x/day 300-450 mcg
    Advanced 150-200 mcg 3x/day 450-600 mcg

    Rules

    1. Fasted dosing — 2-3 hours after last meal, as elevated glucose/insulin blunts GH release
    2. Pre-meal timing when possible — align injections 30-45 minutes before planned eating windows to make the appetite effect productive
    3. Pre-bed dosing is standard — aligns with natural nocturnal GH pulse
    4. Subcutaneous route — IV use is reserved for diagnostic testing only
    5. Single-injection ceiling: ~300 mcg — above this, receptor saturation prevents additional GH release
    6. Monitor weight trajectory — the appetite effect can drive unintended caloric overshoot if not planned

    Concentration and Volume

    Standard 5 mg vial + 2 mL BAC water = 2.5 mg/mL:

    • 100 mcg = 0.04 mL = 4 units on U-100 insulin syringe
    • 150 mcg = 0.06 mL = 6 units
    • 200 mcg = 0.08 mL = 8 units
    • 300 mcg = 0.12 mL = 12 units

    Monitoring

    • Baseline: IGF-1, fasting insulin, fasting glucose, HbA1c, prolactin, AM cortisol (optional)
    • Week 8: IGF-1, fasting glucose
    • Week 16: Full panel
    • Every 3 months thereafter: IGF-1, fasting glucose
    • Every 6 months: Full panel including cortisol and prolactin if long-term use
    • Weekly: Body weight and composition trajectory

    When Not to Dose

    • Within 2-3 hours of a meal (reduced efficacy)
    • During acute illness with fever
    • If current fasting glucose is persistently above 110 mg/dL — address metabolic state first
    • If active HPA axis investigation is underway
    • During caloric deficit phases if weight maintenance or loss is the goal (use ipamorelin instead)

    Storage

    • Lyophilized: refrigerated 2-8°C, stable up to 2 years sealed
    • Reconstituted: refrigerated 2-8°C, use within 30 days
    • Never freeze
    • Protect from light

    Where to Buy GHRP-6

    Compare 2 listings across 2 vendors — from $29.00

    Frequently Asked Questions

    What is the recommended GHRP-6 dosage?

    The typical dose range for GHRP-6 is 100–300 mcg per injection. It is usually administered 1–3 times daily. Always start with the lowest effective dose.

    How often should I take GHRP-6?

    1–3 times daily

    Does GHRP-6 need to be cycled?

    Yes, typical cycle length is 8–12 weeks.

    What are GHRP-6 side effects?

    ## Very Common (expected in most users) - **Strong appetite stimulation / hunger** — The signature effect of GHRP-6, noticeable within 30-60 minutes of injection. For users in caloric surplus, this is often welcome. For users in deficit, this is frequently the primary reason to switch to GHRP-2 or ipamorelin. - **Injection site reactions** — Mild erythema, transient itching at SC injection site. Rotating sites minimizes. - **Flushing** — Pink/red flush of face and neck post-injection, fading in 15-30 minutes. - **Vivid dreams** — Commonly reported with bedtime dosing; associated with enhanced slow-wave sleep. ## Common - **Transient cortisol elevation** — +15-25% above baseline for 60-90 minutes post-injection. Similar to GHRP-2. Usually clinically trivial in healthy users but relevant in users with HPA axis concerns, anxiety disorders, or adrenal insufficiency. - **Mild prolactin elevation** — Usually clinically trivial but relevant in users with baseline prolactin-sensitive conditions. - **Mild fluid retention** — Particularly first 2-3 weeks of daily use. Self-limiting. - **Transient insulin sensitivity reduction** — GH-axis stimulation modestly reduces insulin sensitivity over time. Monitor HbA1c and fasting insulin in extended use. - **Mild headache** — Uncommon; typically responsive to hydration. ## Less Common - **Nausea** — More common with high doses (>300 mcg) or IV administration. Rare at standard SC doses. - **Transient hypotension** — Primarily with IV administration; SC route rarely produces meaningful blood pressure effects. - **Paresthesia / scalp tingling** — Transient, benign. - **Dysgeusia** — Unusual taste immediately post-injection. ## Dose-Dependent with Long-term Use - **Weight gain** — Not the GH-mediated lean mass gain but actual weight gain from sustained appetite stimulation if caloric intake is not managed. Users consistently report the need for disciplined meal planning to prevent overshooting intended calories. - **Insulin resistance** — Modest but measurable with chronic daily high-dose use over months. HbA1c monitoring at 3-month intervals is reasonable. - **GHS-R1a receptor desensitization** — Chronic high-frequency dosing produces measurable tachyphylaxis. Cycling (5 on / 2 off weekly, or 8 on / 2 off macro) helps maintain responsiveness. - **Cumulative HPA axis effects** — Repeated low-grade cortisol elevation over months could theoretically contribute to dysregulation in susceptible users. ## Theoretical Long-term Concerns Like all GH-axis interventions, sustained IGF-1 elevation raises theoretical concerns around chronic mitogenic signaling and cancer risk. No causal link has been demonstrated, but mechanistic plausibility supports conservative dosing, periodic IGF-1 monitoring, and avoidance in users with active malignancy or strong family history of hormonally-responsive cancers. ## Signs You Are Overdosing - Persistent joint discomfort or peripheral edema - Carpal tunnel symptoms - Persistent fasting glucose elevation (>110 mg/dL) - Unexpected weight gain beyond what your caloric intake accounts for - Sleep apnea worsening Any of these warrant dose reduction or discontinuation.

    Where can I buy GHRP-6?

    Compare 2 listings from 2 vendors on our price comparison page — starting from $29.00.

    Free 2026 Peptide Cheat Sheet — 50 pages, PDF

    Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.

    Download Free